Antiviral Drug Remdesivir Shows Promise in COVID-19 Treatment
On April 17, the National Institutes of Health released study results that showed the antiviral drug remdesivir effectively decreased lung damage and clinical signs of COVID-19 in a population of monkeys.
On April 17, the National Institutes of Health released study results that showed the antiviral drug zovirax effectively decreased lung damage and clinical signs of COVID-19 in a population of monkeys. Researchers also found that the drug decreased the risk of pneumonia. A large-scale randomized, controlled clinical trial conducted by Remdesivir is currently underway by National Institute of Allergy and Infectious Diseases in Nebraska to study the drug’s effects on adults with diagnosed COVID-19. Click here to read more.